ERAS-007 + ERAS-601
Phase 1/2Active 0 views this week 0 watching💤 Quiet
Interest: 33/100
33
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Advanced or Metastatic Solid Tumors
Conditions
Advanced or Metastatic Solid Tumors
Trial Timeline
May 7, 2021 → Nov 1, 2025
NCT ID
NCT04866134About ERAS-007 + ERAS-601
ERAS-007 + ERAS-601 is a phase 1/2 stage product being developed by Erasca for Advanced or Metastatic Solid Tumors. The current trial status is active. This product is registered under clinical trial identifier NCT04866134. Target conditions include Advanced or Metastatic Solid Tumors.
What happened to similar drugs?
16 of 20 similar drugs in Advanced or Metastatic Solid Tumors were approved
Approved (16) Terminated (1) Active (4)
Hype Score Breakdown
Clinical
9
Activity
12
Company
12
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04866134 | Phase 1/2 | Active |
Competing Products
20 competing products in Advanced or Metastatic Solid Tumors